HRccine was administered subcutaneously to rats for 4 weeks at dose levels of 300, 60 and 12 times the expected clinical dose to evaluate the subacute toxicity. There were no treatment-related effects in clinical signs, body weight changes, food consu...
HRccine was administered subcutaneously to rats for 4 weeks at dose levels of 300, 60 and 12 times the expected clinical dose to evaluate the subacute toxicity. There were no treatment-related effects in clinical signs, body weight changes, food consumption, water consumption, urinalysis and blood biochemistry in any dose groups. In hematological examinations, increase of leucocyte counts and decrease of hemoglobin concentration were observed in the high dose-treated group. However, no treatment-attributable pathological changes were observed in microscopic examinations. The no-effect dose in subacute toxicity study of rats was considered to be 300 times the expected clinical dose.